Twist Bioscience Bundle
Who Really Controls Twist Bioscience?
Unraveling the ownership structure of a company like Twist Bioscience, a prominent synbio company, is key to understanding its strategic direction and future potential. Knowing who holds the reins provides crucial insights into the company's long-term vision and risk tolerance. The recent spin-out of its DNA data storage technology into Atlas Data Storage in May 2025 underscores the importance of understanding these ownership dynamics.
Founded in 2013, Twist Bioscience, headquartered in South San Francisco, has revolutionized gene synthesis using a proprietary semiconductor-based manufacturing process. This innovative approach has positioned the biotechnology company to serve diverse sectors, including pharmaceuticals and diagnostics. To understand the company's financial health and strategic positioning, consider exploring a detailed Twist Bioscience SWOT Analysis, which provides valuable insights into its strengths, weaknesses, opportunities, and threats. Understanding the evolution of Twist Bioscience ownership, including its founders, key investors, and public shareholders, is critical for assessing its future trajectory.
Who Founded Twist Bioscience?
The synbio company, Twist Bioscience, was established in 2013. The company's mission was to revolutionize synthetic biology through innovative DNA synthesis solutions. The founders' vision and early investments were crucial in shaping the company's trajectory.
The founders of Twist Bioscience brought a wealth of experience to the table. Emily Leproust, the CEO, contributed her expertise in DNA synthesis, while Bill Banyai and Bill Peck added their skills in technology development and genomics, respectively. Floyd Romesberg is also noted as a founder.
Early ownership of Twist Bioscience was primarily held by its founders and early investors. These initial stakeholders played a pivotal role in guiding the company's strategic direction and fostering innovation. The early funding rounds were instrumental in supporting research, development, and the expansion of operations.
Founders
Twist Bioscience was founded by Emily Leproust, Bill Banyai, Bill Peck, and Floyd Romesberg.
Early Vision
The company aimed to revolutionize synthetic biology by providing high-quality, cost-effective DNA synthesis solutions.
Early Investors
Early investors included ARCH Venture Partners, Illumina Ventures, and Fidelity Management & Research Company.
Funding Rounds
In 2015, Twist Bioscience raised $37 million in Series C financing, and in 2017, it secured $61 million in a Series D funding round.
Silicon-Based DNA Synthesis
These early investments underscored investor confidence in Twist Bioscience's disruptive silicon-based DNA synthesis platform.
Public Offering
Twist Bioscience went public in 2018.
Ownership and Investment Milestones
The initial ownership of Twist Bioscience was primarily held by the founders and early investors. Early investors included venture capital firms and strategic partners. These early investments were crucial for the company's growth. To understand the business model and revenue streams, you can read more in this article: Revenue Streams & Business Model of Twist Bioscience.
- Who owns Twist Bioscience has evolved over time, with the founders and early investors holding significant stakes initially.
- The company's early funding rounds, including Series C and D, were instrumental in supporting research, development, and expansion.
- The company's innovative silicon-based DNA synthesis platform attracted significant investor confidence.
- Twist Bioscience's initial public offering (IPO) in 2018 marked a significant milestone in its financial journey.
Twist Bioscience SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Twist Bioscience’s Ownership Changed Over Time?
The journey of Twist Bioscience, a prominent synbio company, into the public domain began on October 31, 2018. The company initiated its public offering on the Nasdaq Global Select Market under the ticker 'TWST'. The initial public offering (IPO) saw the sale of 5 million shares, priced at $14.00 each, which valued the company at approximately $381 million. This pivotal event marked a significant shift in the company's ownership structure, opening it up to a broader range of investors and setting the stage for future growth and market influence. As of June 13, 2025, the company's market capitalization has grown to $2.01 billion, reflecting its expansion and market performance.
The ownership of Twist Bioscience, a leading biotechnology company, is a mix of institutional investors, insiders, and individual shareholders. A major portion of the stock is held by institutional investors, who play a significant role in the company's financial dynamics and strategic direction. Insiders hold a smaller percentage, while public companies and individual investors make up a substantial portion of the shareholder base. The influence of these major shareholders can affect the company's decision-making and stock price.
| Shareholder Category | Approximate Ownership (as of March 31, 2025) | Notes |
|---|---|---|
| Institutional Investors | Significant | Includes Ark Investment Management LLC, The Vanguard Group Inc., and others. |
| Insiders | ~3.23% | Includes company executives and board members. |
| Public Companies & Individual Investors | ~39.94% | Represents the remaining shares held by the public. |
The ownership structure of Twist Bioscience highlights the diverse interests involved in the company's success. Major institutional investors, such as Ark Investment Management LLC, holding 6,241,595 shares as of March 31, 2025, and The Vanguard Group Inc., with 5,867,459 shares, are key players. BlackRock's ownership, reported at 10.90% (6.21 million shares) as of April 6, 2023, demonstrates the significant influence of these large shareholders on the company's strategic direction and market performance. Understanding the dynamics of Twist Bioscience ownership is crucial for anyone interested in the synthetic biology and gene synthesis fields.
Key Takeaways on Twist Bioscience Ownership
The ownership of Twist Bioscience is primarily composed of institutional investors, insiders, and individual shareholders.
- Institutional investors hold a significant portion of the company's stock, influencing decision-making and stock performance.
- Insiders own a smaller percentage, while public and individual investors make up a considerable portion.
- Understanding the ownership structure is vital for those interested in the biotechnology company and its future. For more insights, check out the Growth Strategy of Twist Bioscience.
Twist Bioscience PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Twist Bioscience’s Board?
The Board of Directors at Twist Bioscience Corporation oversees the company's strategy and governance. The board, whose size is determined by its bylaws, is committed to having a majority of independent directors, in line with Nasdaq's listing standards. The Nominating and Corporate Governance Committee is responsible for finding and evaluating potential director candidates.
As of 2025, the Board includes Rob Chess, Nelson C. Chan, Keith Crandell, Jan Johannessen, Bob Ragusa, Melissa Starovasnik, Ph.D., and Emily Leproust. Emily Leproust, a co-founder, serves as CEO. Nelson C. Chan, Jan Johannessen, and Robert Ragusa are on the Audit Committee. The Compensation Committee includes Robert Chess, Keith Crandell, Robert Ragusa, and Melissa Starovasnik, while Rob Chess, Keith Crandell, and Jan Johannessen are part of the Nominating and Corporate Governance Committee. Understanding the Growth Strategy of Twist Bioscience can offer further insights into the company's direction.
| Board Member | Role | Committee Membership |
|---|---|---|
| Rob Chess | Director | Compensation, Nominating and Corporate Governance |
| Nelson C. Chan | Director | Audit |
| Keith Crandell | Director | Compensation, Nominating and Corporate Governance |
| Jan Johannessen | Director | Audit, Nominating and Corporate Governance |
| Bob Ragusa | Director | Audit, Compensation |
| Melissa Starovasnik, Ph.D. | Director | Compensation |
| Emily Leproust | CEO & Director | None |
Twist Bioscience operates with a single class of common stock, where each share has one vote. The company has a declassified board, with all directors elected annually, and uses a majority voting standard. If the Chairperson isn't independent, the independent directors choose a lead independent director. The company also has stock ownership guidelines for its directors. There have been no recent major proxy battles or activist investor campaigns that have significantly changed the company's decision-making.
Key Takeaways on Twist Bioscience's Board
The Board of Directors at Twist Bioscience is structured to ensure independent oversight and strategic direction.
- Majority of independent directors align with Nasdaq standards.
- Committees focus on audit, compensation, and governance.
- Single class of stock ensures equal voting rights.
- Declassified board with annual elections.
Twist Bioscience Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Twist Bioscience’s Ownership Landscape?
Over the past few years, significant strategic shifts have influenced the ownership dynamics of Twist Bioscience. A key development in May 2025 was the spin-out of its DNA data storage technology into a separate entity, Atlas Data Storage. This strategic move allows Twist Bioscience to retain a stake in Atlas, holding approximately a 24% equity interest on a fully diluted basis. This includes potential future financial benefits through technology and commercial milestone payments, as well as royalties on Atlas's future sales. Emily Leproust, CEO and co-founder of Twist Bioscience, is on the board of directors of Atlas, with Bill Banyai, co-founder and former General Manager of DNA data storage at Twist Bioscience, becoming Atlas's CTO. This spin-out is expected to accelerate Twist Bioscience's path toward adjusted EBITDA breakeven by the end of fiscal 2026.
The biotechnology sector, including Twist Bioscience, has seen an increase in institutional ownership. As of March 31, 2025, institutional investors collectively held a substantial percentage of the company's stock. This trend reflects a broader market movement where large investment firms are taking significant positions in biotechnology and synthetic biology companies. While specific founder dilution figures aren’t readily available, the rise in institutional ownership usually indicates a gradual reduction of initial founder stakes as the company expands and raises capital. Understanding the Competitors Landscape of Twist Bioscience is also crucial for assessing its market position.
| Financial Metric | Value | Date |
|---|---|---|
| Revenue | $92.8 million | Q2 FY2025 |
| Gross Margin | 49.6% | Q2 FY2025 |
| Cash Position | $257.1 million | March 31, 2025 |
| Average Analyst Price Target | $44.00 | May 6, 2025 |
Twist Bioscience's financial performance in Q2 fiscal year 2025 showed revenue of $92.8 million and a gross margin of 49.6%, nearing its target of exceeding 50% by the end of fiscal 2025. The company's strong cash position of $257.1 million as of March 31, 2025, reflects its financial stability. Analysts have set an average price target of $44.00 as of May 6, 2025, with a range from $33.00 to $50.00. The company is focused on revenue and margin growth, operational execution, platform enhancements, and market expansion.
Spin-Out
The spin-out of the DNA data storage technology into Atlas Data Storage, with Twist Bioscience retaining a 24% equity interest.
Institutional Ownership
Increasing institutional ownership in Twist Bioscience, reflecting broader market trends in the biotechnology sector.
Financial Performance
Q2 FY2025 revenue of $92.8 million, gross margin of 49.6%, and a cash position of $257.1 million as of March 31, 2025.
Analyst Price Targets
Average analyst price target of $44.00 as of May 6, 2025, with a range from $33.00 to $50.00.
Twist Bioscience Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Twist Bioscience Company?
- What is Competitive Landscape of Twist Bioscience Company?
- What is Growth Strategy and Future Prospects of Twist Bioscience Company?
- How Does Twist Bioscience Company Work?
- What is Sales and Marketing Strategy of Twist Bioscience Company?
- What is Brief History of Twist Bioscience Company?
- What is Customer Demographics and Target Market of Twist Bioscience Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.